ConductScience.org, home

Library / Trials

Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant

NCT01392872, Not applicable, Completed, University Hospital, Clermont-Ferrand

Trial 10

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

FieldValueSource
TitleCognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With ImmunosuppressantClinicalTrials.gov
NCT numberNCT01392872ClinicalTrials.gov
StatusCompletedClinicalTrials.gov
PhasesNot applicableClinicalTrials.gov
Enrollment48 participants, actualClinicalTrials.gov
Lead sponsorUniversity Hospital, Clermont-FerrandClinicalTrials.gov
ConditionsMultiple Sclerosis, Relapsing-RemittingClinicalTrials.gov
InterventionsNeuropsychological assessmentClinicalTrials.gov
First posted2011-07-13ClinicalTrials.gov
Last updated2026-08-05ClinicalTrials.gov

Registered outcomes 12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescriptionSource
PrimaryEvolution of the quality of life of patients diagnosed with relapsing MS and starting a treatment with immunosuppressanton a 36 months periodClinicalTrials.gov
SecondaryAnalysis of variance for repeated measurement15 to 30 days before the beginning of treatment, after 36 monthsClinicalTrials.gov
SecondarySelective Reminding Test (SRT)15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 monthsClinicalTrials.gov
SecondaryDelayed recall of SRT15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 monthsClinicalTrials.gov
SecondaryVisuo-spatial span15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 monthsClinicalTrials.gov
SecondaryDigit span15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 monthsClinicalTrials.gov
SecondaryReverse span15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 monthsClinicalTrials.gov
SecondaryStroop test15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 monthsClinicalTrials.gov
Secondary• Tiredness (EMIF SEP scale): Analysis of variance for repeated measurement15 to 30 days before the beginning of treatment, 1st day of treatment, after 6,12,18 and 36 monthsClinicalTrials.gov
Secondary• Physical function (9HPT, 8 meter walk) : Analysis of variance for repeated measurement15 to 30 days before the beginning of treatment, 1st day of treatment, after 6,12,18 and 36 monthsClinicalTrials.gov
SecondaryDisability (EDSS) : Analysis of variance for repeated measurement15 to 30 days before the beginning of treatment, 1st day of treatment, after 6,12,18 and 36 monthsClinicalTrials.gov
Secondary• Psychological disorder (Beck depression inventory, COVI scale, Depressive scale) : Analysis of variance for repeated measurement15 to 30 days before the beginning of treatment, 1st day of the treatment, after 6,12,18 and 36 monthsClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured asSource

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnitsSource

Participant flow 0

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits countedSource

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEventsSource

Adverse event totals 0

The totals the trial posted for each group.

TotalGroupAffectedAt riskSource

Papers 1

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource
29111011RESULTPubMed

Grants 0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

ProjectTitlePrincipal investigatorsOrganizationFunderFiscal yearsSource

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource

Tests 3

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed asSource
Digit Span TestSecondary outcomeConductCognition
Selective Reminding TaskSecondary outcomeConductCognition
Stroop Color-Word TestSecondary outcomeConductCognition

Source 5

FieldValueSource
Releasetrials-2026-11-12-0.4.0ClinicalTrials.gov
Release manifest SHA-2560f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4ClinicalTrials.gov
Registry capture2026-11-12ClinicalTrials.gov
Results copy, AACT2026-03-23ClinicalTrials.gov
NIH clinical studies file2026-11-13ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)